MitoQ vs CoQ10
The Importance of Mitochondria-Targeted Antioxidants
Coenzyme Q10 (CoQ10) and mitoquinol (MitoQ) share the same redox-active quinone head, but they are built to solve different problems. CoQ10 is an endogenous electron carrier and membrane antioxidant, and oral supplementation aims to replete stores that can fall with age, statin use and certain genetic defects.¹,² Its large, highly lipophilic structure limits intestinal absorption and gives it no specific route into mitochondria.¹
Mitoquinol attaches a shortened quinone to a lipophilic triphenylphosphonium cation, which uses the mitochondrial membrane potential to concentrate the molecule at the inner mitochondrial membrane, where much of the cell’s reactive oxygen species are produced.⁴,¹⁷ The molecules are therefore not interchangeable: CoQ10 can restore electron transport in deficiency, whereas mitoquinol is a targeted, recyclable antioxidant that does not substitute for CoQ10 in the respiratory chain.⁵,⁶ Head-to-head human data remain limited to a single six-week trial.⁸
Is MitoQ Just a Better CoQ10?
For many practitioners, CoQ10 is the default mitochondrial supplement. It has decades of clinical use, a reassuring safety record and a landmark outcome trial in chronic heart failure.³ So when patients ask whether mitoquinol is simply “a better CoQ10,” the more useful question is what each molecule is designed to do once it is swallowed. A supplement can only act where it arrives. CoQ10 has to cross the gut wall, travel in lipoproteins, enter cells and then reach the inner mitochondrial membrane, and each step loses a share of the dose.¹ Mitoquinol was engineered specifically to shortcut the final, hardest step.⁴
This means that these two molecules answer different problems. A patient with depleted CoQ10 needs the electron carrier itself replaced. A patient whose mitochondria are intact but under sustained oxidative pressure (as in vascular ageing or high training loads) may benefit more from an antioxidant directed at the source of that pressure.¹⁰,¹¹ Understanding the delivery problem is what lets a practitioner choose, combine or sequence these antioxidants.
Why CoQ10 Struggles to Reach the Mitochondria
The Problem with Delivering CoQ10 to the Inner Mitochondrial Membrane
Mitochondria generate ATP by passing electrons along the electron transport chain (ETC) in the inner mitochondrial membrane. CoQ10 sits at the centre of that process. It collects electrons from complexes I and II and carries them to complex III.¹ In its reduced form, ubiquinol, it also protects membrane lipids from peroxidation and helps regenerate vitamin E.¹
The same electron flow is an unavoidable source of reactive oxygen species (ROS). Small amounts act as signals; larger or sustained amounts damage cardiolipin, membrane lipids, proteins and mitochondrial DNA.¹⁷ The antioxidant defense therefore needs to work inside the inner membrane, not merely in plasma.
This is where oral CoQ10 meets its limits. It is one of the most hydrophobic molecules in the body, with a 50-carbon isoprenoid tail. Absorption depends on bile, dietary fat and formulation, and is low and saturable at higher single doses.¹ Once absorbed, CoQ10 travels in lipoproteins and enters tissues slowly. No dedicated transporter carries it into mitochondria, and raising plasma levels does not reliably raise levels in heart, muscle or brain mitochondria.¹,²
CoQ10 Repletion vs Mitochondrial Targeting
The two molecules take different routes to the same membrane: CoQ10 supplementation is a repletion strategy, providing enough substrate that some reaches tissues and tops up the endogenous stores – it is most compelling when stores are low.²,³
Mitoquinol is a targeted strategy. It keeps the redox-active quinone head but replaces the long isoprenoid tail with a ten-carbon chain linked to triphenylphosphonium (TPP⁺), a lipophilic cation. That cation lets it cross membranes easily and accumulate according to membrane potential, so it concentrates in mitochondria rather than distributing passively.⁴,¹⁷
For CoQ10, success means a restored electron carrier pool: electron flow from complexes I and II to complex III recovers and ATP output follows. For mitoquinol, success means lower mitochondrial oxidative stress at the inner membrane, with less lipid peroxidation and DNA damage, while normal ROS signalling is preserved.⁵,¹⁰
How MitoQ and CoQ10 Work: Absorption, Uptake and Redox Cycling
CoQ10 is absorbed like a dietary fat. It must be solubilised into bile-salt micelles, taken up by enterocytes, packaged into chylomicrons and delivered to the lymph.¹ Each stage is inefficient for a molecule this large and insoluble. Absorption is improved by taking CoQ10 with a fat-containing meal and by formulations that disperse its crystals; poorly dispersed crystalline CoQ10 can lose roughly three-quarters of its bioavailability.¹ Because uptake is saturable, divided doses usually outperform a single large dose.¹ The reduced form, ubiquinol, is often marketed as better absorbed, but the two forms interconvert in the gut and circulation, and comparative studies are mixed and heavily formulation-dependent.¹
Mitoquinol is a smaller amphiphilic cation that crosses membranes more readily, and plasma concentrations peak within about an hour of an oral dose.¹⁹ In mice, oral mitoquinol produced substantially higher mitochondrial levels than CoQ10 at a tenth of the dose.⁷ However, that comparison has not been replicated in human tissue.
How MitoQ Enters Mitochondria: TPP⁺ and Membrane Potential
The TPP⁺ cation is the defining feature of mitoquinol. Its positive charge is spread over three phenyl rings, so the molecule passes through lipid bilayers without a transporter.¹⁷ Uptake follows the Nernst relationship: roughly a tenfold accumulation for every 60 mV of membrane potential. The plasma membrane potential (about 30–60 mV, negative inside) concentrates it modestly in the cytosol. The far larger mitochondrial potential (about 150–180 mV) concentrates it several hundred-fold in the mitochondrial matrix.⁴,¹⁷ The molecule then adsorbs to the matrix face of the inner membrane, with its quinone head inserted into the lipid core.⁶
Because uptake depends on membrane potential, mitoquinol accumulates most where mitochondria are numerous and actively producing energy, such as the heart, skeletal muscle, liver, kidney and brain.¹⁸ Conversely, severely damaged mitochondria with substantially reduced membrane potential are likely to accumulate less mitoquinol.
Does MitoQ Replace CoQ10 in the Electron Transport Chain?
No - CoQ10 keeps the energy-producing chain running, and mitoquinol protects the membrane that chain sits in. CoQ10 is an electron carrier, and it picks up electrons at complexes I and II and drops them off at complex III inside the electron transport chain. That pick-up and drop-off cycle is what keeps the chain moving and ATP being made.
Mitoquinol can only do half of that job. Complex II loads it with electrons efficiently. However, its bulky TPP⁺ group sits near the membrane surface and holds the quinone head out of reach of complexes I and III, so it unloads electrons there only very slowly.⁵,⁶ Because it can’t pass electrons along the chain, mitoquinol can’t restore energy production in mitochondria that are short of CoQ10.⁵
What it does instead is act as a recyclable antioxidant. In its active (ubiquinol) form, it gives up a hydrogen atom to neutralise lipid radicals. This stops the chain reaction of lipid peroxidation that would otherwise damage mitochondrial membranes. Complex II then reloads the spent molecule and returns it to its active form, ready to neutralise another radical. This recycling is why a small dose can go a long way.⁵,¹⁷
MitoQ Safety, Dose and Pro-oxidant Potential
Like other quinones, mitoquinol is not purely an antioxidant. At very high concentrations, well above anything reached with oral supplements, laboratory studies show it can generate free radicals (superoxide) rather than neutralise them. Its TPP⁺ group can also slightly weaken the mitochondrial membrane’s charge.⁵ These findings come from isolated mitochondria, not people, but they are a reminder that more is not always better and that results from cell studies don’t translate directly to supplement doses. At intended intakes, mitoquinol mesylate has shown no genetic toxicity in laboratory tests, and a 39-week oral toxicity study in animals found it safe.¹⁵
MitoQ vs CoQ10 in a Head-to-Head Human Trial
The clearest direct comparison comes from a New Zealand trial in healthy, middle-aged, untrained men.⁸ Participants took 20 mg/day of mitoquinol, 200 mg/day of CoQ10 or placebo for six weeks. Researchers then took muscle biopsies and measured mitochondrial hydrogen peroxide (H₂O₂), respiration and systemic oxidative stress markers.
Both supplements lowered net mitochondrial H₂O₂ during leak respiration, the state in which ROS output is typically highest. Only mitoquinol also increased muscle catalase, an enzyme that breaks down H₂O₂ and is part of the cell’s own antioxidant defence. Mitoquinol produced these effects at one-tenth of the CoQ10 dose. However, neither supplement changed mitochondrial respiration, urinary F₂-isoprostanes or plasma TBARS.⁸
That pattern demonstrates that in people with no deficiency and normal mitochondrial function, neither molecule is expected to raise ATP capacity. What changes is the redox environment around the mitochondria and later trials in similar populations built on this:
In untrained men, 20 mg/day of mitoquinol during training augmented exercise-induced PGC-1α signalling and improved gains in peak power, without changing mitochondrial content.⁹ In trained cyclists, it improved 8 km time-trial performance.¹⁶ After high-intensity exercise, it reduced mitochondrial and nuclear DNA damage in lymphocytes.¹⁰
This example also highlights that exercise-induced ROS are partly the signal for adaptation. Broad, high-dose antioxidants can blunt that signal, which is why targeting and modest dosing matter more than maximal suppression.
CoQ10 Deficiency vs Mitochondrial Oxidative Stress
Two different failures can sit behind mitochondrial dysfunction:
Carrier depletion: primary CoQ10 deficiencies are rare genetic disorders of CoQ10 synthesis. Secondary depletion is more common and can arise with ageing, statin therapy (statins inhibit HMG-CoA reductase, upstream of both cholesterol and CoQ10 synthesis) and some chronic diseases.² Here, electron transfer itself is limited, and replacing CoQ10 is the logical response.
Oxidative overload with an intact carrier pool: electron flow continues, but ROS production outpaces local defenses. Lipid peroxidation damages cardiolipin and membrane integrity, oxidised mitochondrial DNA accumulates, and redox-sensitive signalling shifts toward inflammation and endothelial dysfunction.¹⁷ Adding more CoQ10 to stores that are already adequate does little to change the redox balance at the inner membrane. A targeted antioxidant like mitoquinol is better matched to this problem.
In practice these states overlap, especially in older adults. A person on long-term statin therapy may have both reduced CoQ10 and elevated vascular oxidative stress.
Conditions Linked to CoQ10 Depletion and Mitochondrial ROS
| Dysregulated process | Conditions investigated | Why they may be connected |
|---|---|---|
| CoQ10 depletion | Primary CoQ10 deficiencies; statin-associated muscle symptoms; chronic heart failure | Reduced carrier limits electron transfer. Strongest CoQ10 outcome evidence is in heart failure; statin myopathy trials are mixed2,3 |
| Mitochondrial ROS and endothelial dysfunction | Age-related vascular stiffness; hypertension; peripheral artery disease | Mitochondrial ROS reduce nitric oxide availability. Mitoquinol improved endothelial function in older adults; trials are small and short11,13 |
| Oxidative damage to kidney and liver | Chronic kidney disease; hepatitis C | High-energy organs accumulate mitoquinol. Pilot and phase II data show vascular and ALT changes, not hard outcomes12,14 |
| Exercise-related oxidative stress | Training load; sarcopenia-prone ageing | Mitoquinol reduced DNA damage and improved power in small trials; clinical relevance in frail populations is untested9,10 |
Choosing Between MitoQ and CoQ10 in Clinic
| Feature | CoQ10 (ubiquinone/ubiquinol) | Mitoquinol (MitoQ) |
|---|---|---|
| Structure | Quinone head with a 50-carbon isoprenoid tail | Quinone head with a 10-carbon chain linked to TPP+ |
| Typical studied dose | 100–300 mg/day, often divided1,3 | 10–20 mg/day (up to 40–80 mg in some trials)8,13,14 |
| Absorption | Low, saturable, fat- and formulation-dependent1 | Rapid; plasma peak around one hour19 |
| Route into mitochondria | No dedicated transporter; slow tissue uptake1 | Driven by membrane potential; several hundred-fold matrix accumulation4 |
| Role in the ETC | Electron carrier between complexes I/II and III | Reduced by complex II, poorly oxidised by complex III; not a substitute5,6 |
| Primary action | Repletes electron carrier pool; membrane antioxidant | Recyclable antioxidant at the inner membrane |
| Strongest human evidence | Chronic heart failure outcomes3 | Vascular function, exercise and oxidative-damage markers9,10,11 |
Lifestyle and Medication Factors that Affect CoQ10 and Mitochondrial Redox
| Factor | Potential role | Evidence and cautions |
|---|---|---|
| Regular aerobic and resistance exercise | Expands mitochondrial content and endogenous antioxidant capacity | Strongest human evidence of any intervention here; should come first |
| Dietary fat with CoQ10 | Improves micellar absorption of CoQ10 | Practical and low-cost; formulation matters as much as timing1 |
| Statin therapy | Lowers CoQ10 synthesis | Supplementing is reasonable; evidence for symptom relief is inconsistent2 |
| Ageing, smoking, metabolic disease | Raise mitochondrial ROS and lower antioxidant reserve | Context for targeted antioxidant use, not an indication on its own |
| High-dose untargeted antioxidants around training | May blunt exercise adaptation | Separate timing from training or favour targeted, modest dosing |
Can MitoQ and CoQ10 be Taken Together?
CoQ10 is the first choice when the aim is repletion: a known or likely deficiency, statin use, or heart failure, where outcome data exist.³ Mitoquinol is the better-matched tool when CoQ10 stores are likely adequate, and the problem is oxidative stress at the mitochondrion - particularly in vascular ageing, high training loads or conditions with documented mitochondrial ROS. The two are complementary because mitoquinol does not replace CoQ10 in the ETC, and using both is mechanistically coherent where depletion and oxidative stress coexist.
Most trials use 20 mg/day of mitoquinol. A practical approach for general cellular health is to start at 10 mg/day and assess response over two to three months.¹⁹ Clinical experience suggests people with chronic fatigue or primary mitochondrial disorders may prefer 5–10 mg/day, as some anecdotal evidence suggests that some find higher doses overly activating.¹⁹
MitoQ vs CoQ10 Research: Current Evidence
CoQ10 is essential for electron transport, and oral absorption is limited and formulation-dependent.¹ In chronic heart failure, 300 mg/day for two years reduced major adverse cardiovascular events in the Q-SYMBIO trial.³
Mitoquinol accumulates in mitochondria in proportion to membrane potential and acts as a recyclable antioxidant, but it cannot replace CoQ10 as an electron carrier.⁴,⁵,⁶
Human mitoquinol trials consistently show changes in oxidative stress markers, endothelial function and exercise performance, typically at 20 mg/day over three to twelve weeks.⁸,⁹,¹⁰,¹¹ Questions remain about which populations respond most, how long effects last after stopping, and whether vascular improvements translate into fewer cardiovascular events.
Only one trial has compared the two molecules directly, and it found similar suppression of mitochondrial H₂O₂, with a catalase advantage for mitoquinol at a tenth of the dose.⁸ The mitochondrial bioavailability advantage comes from mouse data.⁷ No trial yet compares them on clinical outcomes, and long-term human safety data for mitoquinol are shorter than for CoQ10.
Where Mitoquinol fits in Mitochondrial Research
Mitoquinol was developed by Professor Mike Murphy and Dr Robin Smith specifically to solve CoQ10’s delivery problem. Its value lies in placing a recyclable antioxidant on the inner mitochondrial membrane at low oral doses, where untargeted antioxidants struggle to reach meaningful concentrations.⁴,¹⁷
More than 25 human trials have tested mitoquinol, most at 20 mg/day for three to twelve weeks. The strongest and most consistent findings are in vascular function, exercise-related oxidative damage and training response. The only head-to-head trial with CoQ10 found that 20 mg/day of mitoquinol matched 200 mg/day of CoQ10 in lowering muscle mitochondrial H₂O₂, and additionally increased catalase.⁸
| Area | Population | Dose and duration | Main findings |
|---|---|---|---|
| Head-to-head with CoQ10 | Healthy middle-aged men | 20 mg/day vs CoQ10 200 mg/day, 6 weeks | Both lowered muscle mitochondrial H2O2; only mitoquinol raised catalase. Neither changed respiration or systemic oxidative markers8 |
| Vascular ageing | Healthy older adults with impaired endothelial function (n = 20) | 20 mg/day, 6 weeks | Flow-mediated dilation +42%; lower aortic stiffness and oxidised LDL11 |
| Hypertension | Hypertensive men, with or without endurance training (n = 52) | 20 mg/day, 6 weeks | Lower systolic blood pressure, MDA and IL-620 |
| Peripheral artery disease | Patients with PAD (n = 11) | Single 80 mg dose | Improved endothelial function and antioxidant enzyme activity; walking time +74 s13 |
| Heart failure | Heart failure with preserved ejection fraction | 20 mg/day, 4 weeks | Improved immune-cell mitochondrial bioenergetics (conference abstract)23 |
| Kidney | Chronic kidney disease, randomised pilot | 20 mg/day | Improvements in vascular function measures12 |
| Liver | Chronic hepatitis C (n = 30) | 40 or 80 mg/day, 4 weeks | Lower serum ALT, a marker of liver injury14 |
| Oxidative DNA damage | Healthy men, high-intensity exercise | 20 mg/day, 3 weeks | Up to 25% less exercise-induced mitochondrial and nuclear DNA damage10 |
| Antioxidant capacity | Cyclists during vigorous training | 20 mg/day, 6 weeks | ROS reduced by up to 48%; higher glutathione peroxidase activity24 |
| Training response | Untrained middle-aged men, high-intensity training | 20 mg/day | Greater PGC-1α response and larger gains in peak power, without change in mitochondrial content9 |
| Endurance performance | Trained middle-aged cyclists (n = 19) | 20 mg/day, 4 weeks, crossover | 8 km time-trial power +4.4% vs placebo16 |
| Muscle power with age | Late middle-aged and older adults | 20 mg/day, 6 weeks | Leg extension power +11% (conference abstract)26 |
| Muscle damage recovery | Untrained men after eccentric exercise (n = 32) | 20 mg/day, 14 days before exercise | No effect on soreness or force recovery; recovery of eccentric torque was delayed22 |
| Fatigue syndromes | Fibromyalgia and ME/CFS, open-label | 20 mg/day, 12 weeks | Reported less pain and better energy, sleep and cognition (not peer reviewed)25 |
| Neurodegeneration | Parkinson's disease (n = 128) | 40–80 mg/day, 12 months | No effect on disease progression21 |
Read together, these studies show consistent target engagement: lower mitochondrial oxidative stress and less oxidative damage in vascular and muscle tissue. Functional benefits are clearest for endothelial function and training response. Trials are small and short, several are abstracts or open-label, and null results in Parkinson’s disease and muscle-damage recovery show that mitochondrial oxidative stress is not the limiting factor in every condition.
FAQs
Is MitoQ better than CoQ10?
Both antioxidants perform differently. CoQ10 replaces an electron carrier that can run low with age, statins or deficiency. MitoQ (mitoquinol) concentrates an antioxidant inside mitochondria. In the only head-to-head trial, 20 mg of MitoQ matched 200 mg of CoQ10 in lowering muscle mitochondrial H₂O₂, and also raised catalase.⁸
What is the Difference between MitoQ and Ubiquinol?
Ubiquinol is simply the reduced form of CoQ10. It shares CoQ10’s long isoprenoid tail and its absorption limits. MitoQ swaps that tail for a shorter chain linked to a positively charged TPP⁺ group, which drives it into mitochondria using membrane potential.¹,⁴
Can you take MitoQ and CoQ10 Together?
Yes, the combination is mechanistically coherent. MitoQ does not replace CoQ10 in the electron transport chain, so the two do not compete for the same role.⁵ Combining them makes most sense where CoQ10 depletion and mitochondrial oxidative stress coexist, such as in older adults on statins.
How Does the MitoQ Dose Compare to CoQ10?
There is no direct dose equivalence, because the molecules act differently. Most MitoQ trials use 20 mg/day, compared with 100–300 mg/day for CoQ10.³,⁸ A common starting point for general cellular health is 10 mg/day of MitoQ.¹⁹
Should People Taking Statins Use CoQ10 or MitoQ?
Statins lower CoQ10 synthesis, so CoQ10 is the logical first choice for repletion, although trials on statin muscle symptoms are mixed.² MitoQ can be added where vascular or mitochondrial oxidative stress is also a concern.
Key takeaways
CoQ10 and mitoquinol share a quinone head but serve different roles: CoQ10 is an electron carrier to replete, mitoquinol a targeted antioxidant.
CoQ10’s main limitation is delivery: low, saturable absorption and no dedicated route into mitochondria.
Mitoquinol uses membrane potential to concentrate several hundred-fold in mitochondria, but it cannot substitute for CoQ10 in the ETC.
Use CoQ10 for depletion (statins, heart failure, deficiency) and mitoquinol for mitochondrial oxidative stress; the two can be combined.
Direct human comparison rests on one six-week biomarker trial, so claims of superiority should stay proportionate.
References
Mantle D, Dybring A. Bioavailability of coenzyme Q10: an overview of the absorption process and subsequent metabolism. Antioxidants. 2020;9(5):386. doi:10.3390/antiox9050386
Mantle D, Lopez-Lluch G, Hargreaves IP. Coenzyme Q10 metabolism: a review of unresolved issues. Int J Mol Sci. 2023;24(3):2585. doi:10.3390/ijms24032585
Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Fail. 2014;2(6):641–649. doi:10.1016/j.jchf.2014.06.008
Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 2001;276(7):4588–4596. doi:10.1074/jbc.M009093200
James AM, Cochémé HM, Smith RAJ, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. J Biol Chem. 2005;280(22):21295–21312. doi:10.1074/jbc.M501527200
James AM, Sharpley MS, Manas AR, et al. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem. 2007;282(20):14708–14718. doi:10.1074/jbc.M611463200
Woodhead B, Jaiswal J. Mitochondrial bioavailability of mitoquinol mesylate orally administered to mice. Biochim Biophys Acta Bioenerg. 2024;1865(Suppl):149344. EBEC 2024 abstract book, 22nd European Bioenergetics Conference (conference abstract).
Pham T, MacRae CL, Broome SC, et al. MitoQ and CoQ10 supplementation mildly suppresses skeletal muscle mitochondrial hydrogen peroxide levels without impacting mitochondrial function in middle-aged men. Eur J Appl Physiol. 2020;120(7):1657–1669. doi:10.1007/s00421-020-04396-4
Broome SC, Pham T, Braakhuis AJ, et al. MitoQ supplementation augments acute exercise-induced increases in muscle PGC1α mRNA and improves training-induced increases in peak power independent of mitochondrial content and function in untrained middle-aged men. Redox Biol. 2022;53:102341. doi:10.1016/j.redox.2022.102341
Williamson J, Hughes CM, Cobley JN, Davison GW. The mitochondria-targeted antioxidant MitoQ attenuates exercise-induced mitochondrial DNA damage. Redox Biol. 2020;36:101673. doi:10.1016/j.redox.2020.101673
Rossman MJ, Santos-Parker JR, Steward CAC, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71(6):1056–1063. doi:10.1161/HYPERTENSIONAHA.117.10787
Kirkman DL, Stock JM, Shenouda N, et al. Effects of a mitochondrial-targeted ubiquinol on vascular function and exercise capacity in chronic kidney disease: a randomized controlled pilot study. Am J Physiol Renal Physiol. 2023;325(4):F448–F456. doi:10.1152/ajprenal.00067.2023
Park SY, Pekas EJ, Headid RJ, et al. Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease. Am J Physiol Heart Circ Physiol. 2020;319(2):H456–H467. doi:10.1152/ajpheart.00235.2020.
Gane EJ, Weilert F, Orr DW, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019–1026. doi.org/10.1111/j.1478-3231.2010.02250.x
Mitchell ES, Lemke S, Woodhead B, Coleman D. Oral subchronic toxicity study and genetic toxicity evaluation of mitoquinone mesylate. J Appl Toxicol. 2024;44(10):1555–1571.
Broome SC, Braakhuis AJ, Mitchell CJ, Merry TL. Mitochondria-targeted antioxidant supplementation improves 8 km time trial performance in middle-aged trained male cyclists. J Int Soc Sports Nutr. 2021;18:58. doi:10.1186/s12970-021-00454-0
Murphy MP, Smith RAJ. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol. 2007;47:629–656. doi:10.1146/annurev.pharmtox.47.120505.105110
Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96–103. doi:10.1111/j.1749-6632.2010.05627.x
MitoQ. Mitoquinol vs. CoQ10: practitioner guide (healthcare professional document; pharmacokinetic and dosing guidance).

